CIENCIAS FARMACÉUTICAS
Departamento
Alfonso Jesús
Domínguez-Gil Hurlé
Profesor Emérito Honorífico
Publicaciones en las que colabora con Alfonso Jesús Domínguez-Gil Hurlé (113)
2017
-
Medicamentos Falsificados. Todo lo que debemos saber
Farmajournal, Vol. 2, Núm. 1, pp. 135-136
2016
-
Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study
Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39
2015
-
CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman
Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66
2014
-
Facility-based inspection training in a virtual 3D laboratory
Accreditation and Quality Assurance, Vol. 19, Núm. 5, pp. 403-409
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study
Patient Preference and Adherence, Vol. 7, pp. 729-739
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2012
-
Juega a ganar 2.0
Hospital Universitario de Salamanca
2011
-
Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma
Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Terapia personalizada en la infección por el VIH: Aplicación de criterios farmacogenéticos
Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 48, pp. 75-99
2010
-
Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment
Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176
2009
-
Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients
Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis
Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280
2008
-
Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy
Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489
2007
-
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients
Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285
2006
-
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
Clinical Microbiology and Infection, Vol. 12, Núm. SUPPL. 7, pp. 97-106
2005
-
Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies
Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941
2004
-
Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos
Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101